Roche Diagnostics
Roche's global diagnostics business, supplying laboratory, molecular, tissue, diabetes and point-of-care testing systems.
Last updated August 27, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Roche Diagnostics is the diagnostics division and operating brand of the Swiss healthcare group F. Hoffmann-La Roche. It develops, manufactures and commercializes in vitro diagnostic systems, reagents, software and related services for clinical laboratories, hospitals, physicians, researchers and patients. Its activities span routine laboratory testing, molecular diagnostics, tissue diagnostics, diabetes management, point-of-care testing and research technologies. The division's modern structure was established after Roche acquired Corange Ltd in 1998. Corange owned Boehringer Mannheim, a major German healthcare and diagnostics business. Roche retained the diagnostics operations and repositioned Boehringer Mannheim under the Roche Diagnostics name, while selling the DePuy manufacturing business to Johnson & Johnson. That transaction gave Roche a broad installed base in clinical chemistry, immunoassay, blood-glucose monitoring and laboratory workflow products, helping it build a diagnostics platform alongside its pharmaceutical division. Roche Diagnostics is organized around several technology and customer areas. Professional Diagnostics serves hospitals, reference laboratories and physician practices with systems for clinical chemistry, immunochemistry, hematology, coagulation, urinalysis and related laboratory disciplines. Molecular Diagnostics develops nucleic-acid testing platforms, reagents and assays for infectious diseases, oncology, blood screening and other applications. Tissue Diagnostics, associated with Roche's Ventana business, supplies instruments and reagents used in histopathology and immunohistochemistry, including tests that help characterize tumors and guide treatment decisions. Diabetes Care provides blood-glucose monitoring products and digital tools for people living with diabetes. Roche Applied Science has historically supported research and biopharmaceutical laboratories with amplification, sequencing and other laboratory technologies. The cobas family is the division's best-known platform franchise. It includes high-throughput molecular testing systems, clinical chemistry and immunoassay analyzers, and integrated laboratory solutions. The cobas 6800 and cobas 8800 systems became especially visible during the COVID-19 pandemic because they could process large volumes of molecular tests. Roche received United States Food and Drug Administration authorization in 2020 for a high-throughput SARS-CoV-2 test used on these platforms. The business model is based on a combination of capital equipment, proprietary consumables, assay menus, software and service contracts. This creates recurring demand for reagents and supports long-term relationships with laboratories that standardize workflows around Roche systems. The company also participates in decentralized and near-patient testing, digital diabetes management, pathology informatics and data-enabled laboratory operations. Roche Diagnostics operates internationally through Roche affiliates and local legal entities, including subsidiaries using names such as Roche Diagnostics GmbH, Roche Diagnostics Limited, Roche Diagnostics S.L. and Roche Diagnostics Oy. Its principal Swiss diagnostics location is in Rotkreuz. The division remains part of Roche's two-part corporate structure, alongside Pharmaceuticals, and is not a separately listed public company. Public materials describe it as a global diagnostics provider rather than as an independent corporation with its own separately disclosed stock ticker.
History
Roche Diagnostics emerged as a distinct Roche business following the 1998 acquisition of Corange Ltd, the holding company of Boehringer Mannheim. Boehringer Mannheim had substantial activities in medical diagnostics, including laboratory systems, reagents and diabetes care. Roche retained and rebranded those operations as Roche Diagnostics, making diagnostics one of the two principal pillars of the Roche Group alongside Pharmaceuticals. The acquisition broadened Roche's healthcare model beyond medicines. Instead of relying only on pharmaceutical products, Roche could offer laboratories a connected portfolio of analyzers, consumables, assays and services. The diagnostics organization subsequently developed around professional laboratory testing, molecular diagnostics, diabetes care, tissue diagnostics and research technologies. Roche Applied Science addressed academic, biotechnology and pharmaceutical research markets, while the clinical businesses focused on hospitals, reference laboratories, physician offices and patients. Roche's later expansion strengthened the division's technology base. The group acquired Ventana Medical Systems in 2008, adding a major tissue diagnostics platform used in pathology and cancer testing. Roche also made a series of investments and acquisitions in molecular testing, sequencing-related workflows, blood diagnostics and laboratory automation. These activities complemented the established clinical chemistry, immunoassay and glucose-monitoring franchises inherited from Boehringer Mannheim. The cobas brand became the central platform identity across several Roche diagnostics categories. Depending on the configuration, cobas systems support molecular assays, clinical chemistry and immunoassay testing. Their use of common automation, software and consumables enables laboratories to consolidate testing and standardize processes. Roche also developed high-throughput molecular systems, including cobas 6800 and cobas 8800, for laboratories that need to process large numbers of specimens. The COVID-19 pandemic brought the division broad public attention. In 2020, Roche obtained United States authorization for a high-volume SARS-CoV-2 molecular test for use with the cobas 6800 and cobas 8800 platforms. The systems were described as capable of processing approximately 1,400 to 8,800 samples over a 24-hour period, depending on configuration and workflow. This episode illustrated the strategic importance of Roche's installed laboratory base and its ability to deploy assays through existing instruments. Roche continued to expand molecular diagnostics after the pandemic. Its 2021 agreement to acquire GenMark Diagnostics added multiplex molecular testing technology, while the acquisition of TIB Molbiol later that year supported assay development and infectious-disease diagnostics. The division also operates in tissue diagnostics through Ventana, in diabetes management through glucose-monitoring products and digital services, and in research-use technologies serving academic and industrial laboratories. Today, Roche Diagnostics is a global operating division rather than an independently listed company. It sells through Roche's international affiliate network and serves both centralized laboratories and decentralized care settings. Its competitive proposition rests on broad assay menus, large installed instrument platforms, pathology and molecular expertise, laboratory automation, digital connectivity and the recurring consumption of reagents and other testing supplies.
- 2021
GenMark Diagnostics acquisition announced
[4]Roche agreed to acquire GenMark Diagnostics to expand its molecular diagnostics portfolio and multiplex testing capabilities.
- 2021
TIB Molbiol acquisition announced
[5]Roche announced the acquisition of TIB Molbiol, enhancing its molecular assay development and infectious-disease testing activities.
- 2020
High-throughput COVID-19 testing authorization
[3]Roche Diagnostics received United States authorization for a high-volume SARS-CoV-2 molecular test for the cobas 6800 and 8800 systems.
- 2013
Constitution Medical acquisition expands blood diagnostics
[1]Roche Diagnostics acquired Constitution Medical, adding technology and expertise in blood diagnostics.
- 2008
Ventana Medical Systems joins Roche
[1]Roche acquired Ventana Medical Systems, strengthening its position in tissue diagnostics, pathology instruments and related reagents.
- 1998
Boehringer Mannheim becomes the foundation of Roche Diagnostics
[1]Roche acquired Corange Ltd, the parent company of Boehringer Mannheim, and subsequently rebranded the retained diagnostics activities as Roche Diagnostics.
Products and positioning
An integrated, innovation-led global diagnostics provider combining analyzers, assays, laboratory automation, pathology technologies, digital tools and recurring service support.
Molecular diagnostics
cobas molecular diagnostics
The cobas molecular portfolio combines analyzers, reagents and software for nucleic-acid testing. It supports applications including infectious-disease testing, blood screening and selected oncology workflows. The platform family ranges from high-throughput centralized laboratory systems to configurations designed for more flexible testing environments.
High-throughput molecular diagnostics
cobas 6800 and cobas 8800
These automated molecular testing systems are designed for large clinical laboratories. They integrate sample preparation, amplification, detection and result handling, allowing laboratories to process substantial volumes with limited manual intervention. Roche used the platforms for its high-volume SARS-CoV-2 test during the COVID-19 pandemic.
Laboratory diagnostics
cobas clinical chemistry and immunoassay systems
This family covers analyzers and reagent systems used for routine clinical chemistry and immunochemistry testing. Typical laboratory applications include measurement of metabolites, enzymes, hormones, proteins and disease-related markers. The systems are commonly deployed with automation and software intended to improve throughput and standardize laboratory workflows.
Tissue diagnostics
VENTANA tissue diagnostics
VENTANA instruments, stains, antibodies and related reagents support histopathology and immunohistochemistry. The portfolio is used to prepare and characterize tissue specimens, particularly in cancer diagnosis and biomarker assessment. It forms Roche's principal pathology-focused diagnostics franchise.
Diabetes management
Roche diabetes care products
Roche's diabetes-care business provides blood-glucose monitoring devices, test strips and associated digital or data-management tools. These products are intended for people with diabetes and healthcare professionals who monitor glucose levels and support treatment decisions.
Brand decisions
2021
Acquisition of GenMark DiagnosticsM&ABackground
Roche sought to expand its molecular diagnostics offering, particularly in multiplex testing.
Action taken
Roche announced an agreement to acquire GenMark Diagnostics and to retain its principal operations in Carlsbad, California.
Aftermath
The transaction added GenMark's molecular testing capabilities to Roche's diagnostics portfolio.
Announced transaction value. (2021)
2020
Deployment of high-throughput SARS-CoV-2 testingProduct launchBackground
The COVID-19 pandemic created urgent demand for scalable molecular testing capacity.
Action taken
Roche Diagnostics obtained United States authorization for a SARS-CoV-2 test designed for use on cobas 6800 and cobas 8800 systems.
Aftermath
The authorization expanded the use of Roche's high-throughput molecular installed base in pandemic testing programs.
1998
Rebrand of Boehringer Mannheim diagnostics operationsM&ABackground
Roche acquired Corange Ltd, whose principal healthcare asset was Boehringer Mannheim. The transaction provided Roche with a substantial diagnostics platform.
Action taken
Roche retained the diagnostics activities and operated them under the Roche Diagnostics name, while the DePuy manufacturing business was sold to Johnson & Johnson.
Aftermath
The transaction established diagnostics as a core Roche division and gave the group a broad base in laboratory testing, diabetes care and related technologies.
Acquisition value reported for Corange. (1998)
Recent events
Prenosis and Roche Diagnostics expand sepsis diagnostics partnership[6]
Reported:
Prenosis announced an expansion of its existing partnership with Roche Diagnostics, valued at close to $6 million. The companies will expand the NOSIS dataset and work together to seek FDA clearance for the Prenosis Sepsis Immunoscore and Roche Elecsys IL-6 Assay.
Aster DM Healthcare signs partnership with Roche Diagnostics[7]
Reported:
Aster DM Healthcare signed a memorandum of understanding with Roche Diagnostics, making Roche Diagnostics its strategic partner across the UAE, Saudi Arabia, Qatar and Oman. The agreement includes antibody COVID-19 testing, digital solutions and automated laboratory solutions.
FDA approves Roche Diagnostics MMR-deficiency test[8]
Reported:
In a separate regulatory decision, the FDA approved a Roche Diagnostics test that identifies mismatch repair deficiency.
Babyscripts and Roche Diagnostics announce commercial partnership[9]
Reported:
Babyscripts announced a commercial partnership with Roche Diagnostics to collaborate on digital and diagnostic solutions in women's health, including development of Babyscripts' remote patient monitoring programs for pregnancy.
Nimble Therapeutics and Roche Diagnostics announce collaboration on SARS-CoV-2 diagnostic compounds[10]
Reported:
Nimble Therapeutics announced a collaboration with Roche Diagnostics to discover peptide-based molecules for developing SARS-CoV-2 in vitro diagnostic assays. Nimble will provide its peptide synthesis, screening, and optimization platform, while Roche will develop the assays.
Inotrem enters worldwide licensing agreement with Roche Diagnostics[11]
Inotrem announced that it entered a worldwide licensing agreement with Roche Diagnostics for commercialization of a mechanism-based companion diagnostic test using soluble plasma protein sTREM-1.
Sources11 sources
- 1Rocheen.wikipedia.org
- 2Roche Diagnostics official websitediagnostics.roche.com
- 3Roche receives FDA emergency use authorization for cobas SARS-CoV-2 testdiagnostics.roche.com
- 4Roche to acquire GenMark Diagnosticsroche.com
- 5Roche to acquire TIB Molbiolroche.com
- 6Prenosis与Roche Diagnostics扩大败血症诊断合作prnewswire.com
- 7Aster DM Healthcare与Roche Diagnostics签署合作协议gulfnews.com
- 8FDA 批准 Roche Diagnostics 的 MMR 缺陷检测medcitynews.com
- 9Babyscripts与Roche Diagnostics宣布商业合作prweb.com
- 10Nimble Therapeutics与Roche Diagnostics宣布合作开发新冠诊断化合物prnewswire.com
- 11Inotrem与Roche Diagnostics达成全球许可协议biospectrumindia.com
Cite this profile: Cite the canonical profile. /brand-wiki/roche-diagnostics · Editorial policy · How profiles are compiled